Allorion Therapeutics Inc. has patented phosphoramidate macrocycle compounds acting as aldo-keto reductase family 1 member C3 (AKR1C3; 17β-HSD5) inhibitors potentially useful for the treatment of cancer.

Cancer Research Technology Ltd. and My-T Bio Ltd. have discovered Myt1 kinase (PKMYT1) inhibitors potentially useful for the treatment of cancer.

University of Eastern Finland has synthesized carbonic anhydrase II (CA2) inhibitors and melanin ligands. As such, they are described as potentially useful for the treatment of glaucoma, macular edema and retinal degeneration.

SK Biopharmaceuticals Co. Ltd. has identified sodium channel protein type 9 subunit α (SCN9A; Nav1.7) blockers reported to be useful for the treatment of neuropathic pain.

Novartis AG has reported macrocyclic compounds acting as pan-RAS inhibitors and therefore potentially useful for the treatment of cancer.

Researchers at Guangzhou Laboratory and Guangzhou Medical University have described compounds reported to be useful for the treatment of asthma, bronchitis, chronic obstructive pulmonary disease (COPD) and infectious pneumonia.

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has divulged antibody-drug conjugates (ADCs) potentially useful for the treatment of cancer. The ADCs comprise an antibody or antigen-binding fragment linked to a cytotoxic drug through a linker.

Abbisko Therapeutics Co. Ltd. has identified GTPase KRAS inhibitors reported to be useful for the treatment of cancer.

Haisco Pharmaceutical Group Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an EGFR (HER1; erbB1)-targeting moiety through a linker.

Genescience Pharmaceuticals Co. Ltd. has disclosed tachykinin NK3 receptor (TACR3) antagonists reported to be useful for the treatment of attention deficit hyperactivity disorder (ADHD), cancer, convulsions, depression and more.